SARC 006 : Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors
暂无分享,去创建一个
Robin L. Jones | S. Steinberg | D. Reinke | S. Schuetze | J. Ludwig | L. Helman | D. Viskochil | B. Widemann | E. Dombi | C. Moertel | M. Milhem | L. Wagner | A. Perry | D. Rushing | C. Annunziata | S. Goldman | M. Livingston | A. Staddon | David Janhofer | L. Long | C. Higham | L. Baker
[1] J. Blay,et al. sarcomaFull-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial , 2016 .
[2] S. Peltonen,et al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Dafydd G. Thomas,et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma , 2016, Cancer.
[4] D. Reinke,et al. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. , 2015, European journal of cancer.
[5] D. Liebner. The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma , 2015, Journal of surgical oncology.
[6] A. Kim,et al. Current Treatment Options for Malignant Peripheral Nerve Sheath Tumors , 2015, Current Treatment Options in Oncology.
[7] V. Zagonel,et al. Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas. , 2013, Current medicinal chemistry.
[8] K. S. Hall,et al. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1 , 2012, Neuro-oncology.
[9] W. Marsden. I and J , 2012 .
[10] S. Martinez,et al. Influence of Specialty and Clinical Experience on Treatment Sequencing in the Multimodal Management of Soft Tissue Extremity Sarcoma , 2012, Annals of Surgical Oncology.
[11] Andrea Ferrari,et al. Soft tissue sarcoma across the age spectrum: A population‐based study from the surveillance epidemiology and end results database , 2011, Pediatric blood & cancer.
[12] P. Wolkenstein,et al. Evolving Pattern with Age of Cutaneous Signs in Neurofibromatosis Type 1: A Cross-Sectional Study of 728 Patients , 2011, Dermatology.
[13] L. Mariani,et al. Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. , 2011, European journal of cancer.
[14] M. van Glabbeke,et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] Paul A Meyers,et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] L. Qin,et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Citrin,et al. The role of radiation therapy in the management of sarcomas. , 2008, The Surgical clinics of North America.
[18] 宏和 田中,et al. 膵癌を伴った縦隔原発Malignant Peripheral Nerve Sheath Tumor(MPNST)の一例 , 2007 .
[19] S. Devesa,et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978–2001: An analysis of 26,758 cases , 2006, International journal of cancer.
[20] A. Ferrari,et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] K. Khosrotehrani,et al. Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients , 2005, American journal of medical genetics. Part A.
[22] R. Lothe,et al. Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] S. Tripp,et al. Malignant Peripheral Nerve Sheath Tumor: A Comparison of Grade, Immunophenotype, and Cell Cycle/Growth Activation Marker Expression in Sporadic and Neurofibromatosis 1-Related Lesions , 2003, The American journal of surgical pathology.
[24] D. Evans,et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.
[25] V. Bramwell,et al. Dose-intensive chemotherapy in advanced adult soft tissue sarcoma , 2002, Expert review of anticancer therapy.
[26] D. Gutmann,et al. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. , 2002, Cancer research.
[27] M. Kattan,et al. Postoperative nomogram for 12-year sarcoma-specific death. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Evans,et al. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. , 2001 .
[29] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[30] K. Sundby Hall,et al. Chemotherapy in soft tissue sarcomaThe Scandinavian Sarcoma Group experience , 2004, Acta orthopaedica Scandinavica. Supplementum.
[31] M. Campanacci. Malignant Peripheral Nerve Sheath Tumor (MPNST) , 1999 .
[32] Y. Ozisik,et al. Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy. , 1998, Cancer investigation.
[33] J. Neal,et al. Malignant Peripheral Nerve Sheath Tumors (Malignant Schwannomas) in Children , 1992, The American journal of surgical pathology.
[34] R. Wittes,et al. Therapeutic response in phase I trials of antineoplastic agents. , 1986, Cancer treatment reports.
[35] B. Scheithauer,et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases , 1986, Cancer.